REPLIMUNE GROUP INC

Replimune Group Inc. leads oncolytic immunotherapy research—promising cancer breakthroughs amid volatile biotech markets and a negative P/E that underscores its growth‑driven, research‑heavy model.

FDA accepts Replimune’s RP1 BLA for advanced melanoma, promising a new immunotherapy option by Aug 2 2026 and sparking market optimism.

Replimune Group Inc. is pioneering oncolytic immunotherapy to transform cancer treatment. Learn about its market, innovation, and future prospects.

Replimune Group Inc. pioneers oncolytic immunotherapy, aiming to selectively kill cancer cells while sparing healthy tissue. Learn about its clinical trials, market performance, and future oncology impact.

Replimune’s shares tumble 10% after the FDA blocks its skin‑cancer therapy RP1, highlighting the need for controlled trials and exposing investor risk.

Replimune’s second FDA rejection of its RP1 melanoma therapy forces a strategic overhaul—stock drops, layoffs hit, and the company must reshape trials or pivot its pipeline for survival.

Replimune Group’s PDUFA update and breakthrough SITC data boost analyst confidence in its RP1 oncolytic therapy, positioning the company for FDA approval and potential market upside.

Replimune Group Inc. is facing a critical moment as a class action lawsuit is filed, potentially impacting the company’s financial health and stock performance, while also presenting an opportunity for investors to recover losses.

Replimune Group Inc., a biotechnology company, is facing multiple class action lawsuits from investors alleging securities fraud and misrepresentation, amid the company’s financial struggles.

Replimune Group Inc.’s stock plummeted 75% after the FDA rejected its application for a skin cancer treatment, sparking a wave of analyst downgrades and market volatility.